Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07487701 · ClinicalTrials.gov registry record · NA

Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study

A NA study of Migraine and Chronic Migraine, Headache, sponsored by Theranica.

Active
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT07487701 is a NA study of Migraine and Chronic Migraine, Headache that is active but no longer recruiting, run by Theranica. The registered enrollment target is 150 participants, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07487701, a NA study of Migraine and Chronic Migraine, Headache, is active but no longer recruiting, sponsored by Theranica.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited, especially among patients with chronic migraine. Remote electrical neuromodulation (REN) is a non-invasive FDA-cleared wearable device for acute and/or preventive migraine treatment. This study evaluated the real-world efficacy and patient-reported outcomes of preventive REN use over 3 months in chronic migraine population.

Interventions

  • DEVICE Nerivio REN device

Study Locations (1)

New Jersey

  • Theranica Bio-Electronics Inc - Bridgewater

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-02-20
Est. Completion 2026-04-15
Phase NA

Sponsor

Theranica

22 total trials

What the Registry Record Tells You About NCT07487701

The ClinicalTrials.gov registry entry for NCT07487701 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 357-participant average among 102 other Migraine trials with a reported enrollment target (58% lower). The listed sponsor is Theranica, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Nerivio REN device is the first listed.

NCT07487701 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT07487701 about?

NCT07487701 is a clinical study titled "Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study". Preventive pharmacologic therapies for migraine aim to reduce attack frequency and duration and improve quality of life; however, their use, overall benefit and adherence are often limited, especially among patients with chronic migraine. Remote electrical neuromodulation (REN) is a non-invasive FDA...

What is the current status of trial NCT07487701?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2026-02-20. Estimated completion is 2026-04-15.

What conditions does trial NCT07487701 study?

This clinical trial studies the following conditions: Migraine, Chronic Migraine, Headache.

What interventions are being tested in trial NCT07487701?

The interventions under investigation include: Nerivio REN device (DEVICE).

Who is sponsoring clinical trial NCT07487701?

This trial is sponsored by Theranica, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07487701 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.